Source-grounded facts extracted from Organogenesis Holdings Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Organogenesis Holdings Inc. shareholders approved To ratify the appointment of RSM US LLP as our independent registered public accounting firm for fiscal year 2026. at the 2026-06-15 meeting.
“At the Annual Meeting, our stockholders also approved the proposal to ratify the appointment of RSM US LLP as our independent registered public accounting firm for our fiscal year ending on December 31, 2026. The votes cast on this proposal were as follows: Proposal Votes For Votes Against Abstentions Broker Non-Votes To ratify the appointment of RSM US LLP as our independent registered public accounting firm for fiscal year 2026. 128,421,160 856,933 286,328 0”
Shareholder Votes
Organogenesis Holdings Inc. shareholders approved To approve, on an advisory basis, the compensation paid to our named executive officers. at the 2026-06-15 meeting.
“At the Annual Meeting, our stockholders also approved, on an advisory basis, the compensation paid to our named executive officers. The votes cast on this proposal were as follows: Proposal Votes For Votes Against Abstentions Broker Non-Votes To approve, on an advisory basis, the compensation paid to our named executive officers. 72,516,011 12,722,258 61,328 44,264,824”
Shareholder Votes
Organogenesis Holdings Inc. shareholders approved Election of Directors at the 2026-06-15 meeting.
“At the Annual Meeting, each of Robert Ades, Michael J. Driscoll, Prathyusha Duraibabu, Jon Giacomin, Gary S. Gillheeney, Sr., Michele Korfin, Arthur S. Leibowitz, Glenn H. Nussdorf and Gilberto Quintero was elected our Director, to serve until the next Annual Meeting of Stockholders and until their successors are elected and qualified. The votes cast in the election of the directors were as follows: Nominee Votes For Votes Withheld Broker Non-Votes Robert Ades 85,064,304 235,293 44,264,824 Michael J. Driscoll 76,582,548 8,717,049 44,264,824 Prathyusha Duraibabu 76,767,319 8,532,278 44,264,824 Jon Giacomin 64,825,495 20,474,102 44,264,824 Gary S. Gillheeney, Sr. 76,736,718 8,562,879 44,264,824 Michele Korfin 76,707,741 8,591,856 44,264,824 Arthur S. Leibowitz 76,682,590 8,617,007 44,264,824 Glenn H. Nussdorf 61,049,018 24,250,579 44,264,824 Gilberto Quintero 76,572,688 8,726,909 44,264,824”
Earnings Releases
Organogenesis Holdings Inc. reported first quarter ended March 31, 2026 results: revenue $36.3 million, net income Net loss of $53.2 million, EPS $(0.44) per share. Guidance lowered.
“Net revenue of $36.3 million for the first quarter of 2026”
Material Agreements
Organogenesis Holdings Inc. amended First Amendment to Lease with 65 Dan Road SPE, LLC valued at Annual rent in 2027: $1,608,699.84 for 65 Dan Road and $3,161,377.89 for 150 Dan Road; lease term ex (effective 2025-12-22).
“On December 22, 2025, Organogenesis Inc. (“Organogenesis”), a wholly owned subsidiary of Organogenesis Holdings Inc. (the “Company”), entered into a First Amendment to Lease with 65 Dan Road SPE, LLC, as landlord, relating to the premises located at 65 Dan Road, Canton, Massachusetts (the “65 Dan Road Amendment”), and a separate First Amendment to Lease with Dan Road Associates, LLC, as landlord, relating to the premises located at 150 Dan Road, Canton, Massachusetts (the “150 Dan Road Amendment”, together with the 65 Dan Road Amendment, the “Lease Amendments”).”
Garrett Lustig was appointed as Director at Organogenesis Holdings Inc..
“On November 12, 2024, the Board appointed Garrett Lustig to the Board, effective immediately.”
Earnings Releases
Organogenesis Holdings Inc. reported first quarter ended March 31, 2024 results: revenue $110.0 million, net income $2.1 million, EPS $(0.02) per share. Guidance reaffirmed.
“Surgical & Sports Medicine markets, today reported financial results for the first quarter ended March 31st, 2024. First Quarter 2024 Financial Results Summary: • Net revenue of $110.0 million for the first quarter of 2024, an increase of $2.3 million compared to net revenue of $107.6 million for the first quarter of 2023. Net revenue for the first quarter of 2024”
Earnings Releases
Organogenesis Holdings Inc. reported the fiscal year ended December 31, 2023 results: revenue $433.1 million, net income Net income of $4.9 million. Guidance initiated.
“Net revenue of $433.1 million for the year ended December 31, 2023”
Earnings Releases
Organogenesis Holdings Inc. reported the fourth quarter ended December 31, 2023 results: revenue $99.7 million, net income Net loss of $0.6 million.
“Net revenue of $99.7 million for the fourth quarter of 2023”
Earnings Releases
Organogenesis Holdings Inc. reported the third quarter ended September 30, 2023 results: revenue $108.5 million, net income $3.2 million, EPS $0.02 per share. Guidance reaffirmed.
“Net revenue of $108.5 million for the third quarter of 2023”
Earnings Releases
Organogenesis Holdings Inc. reported the fiscal second quarter ended June 30, 2023 results: revenue $117.3 million, net income $5.3 million, or $0.04 per share, EPS $0.04 per share.
“& Sports Medicine markets, today reported financial results for the second quarter ended June 30th, 2023. Second Quarter 2023 Financial Results Summary: • Net revenue of $117.3 million for the second quarter of 2023, a decrease of $4.1 million compared to net revenue of $121.4 million for the second quarter of 2022. Net revenue for the second quarter of 2023”
Shareholder Votes
Organogenesis Holdings Inc. shareholders approved To ratify the appointment of RSM US LLP as the Company’s independent registered public accounting firm for fiscal year 2023 at the 2023-06-13 meeting.
“The votes cast on this proposal were as follows: Proposal Votes For Votes Against Abstentions Broker Non-Votes To ratify the appointment of RSM US LLP as the Company’s independent registered public accounting firm for fiscal year 2023 101,491,715 238,798 85,991 0”
Shareholder Votes
Organogenesis Holdings Inc. shareholders approved To approve, on an advisory basis, the compensation paid to the Company’s named executive officers. at the 2023-06-13 meeting.
“The votes cast on this proposal were as follows: Proposal Votes For Votes Against Abstentions Broker Non-Votes To approve, on an advisory basis, the compensation paid to the Company’s named executive officers. 51,710,250 13,676,178 64,553 36,365,523”
Shareholder Votes
Organogenesis Holdings Inc. shareholders approved Election of Directors at the 2023-06-13 meeting.
“The votes cast in the election of the directors were as follows: Nominee Votes For Votes Withheld Broker Non-Votes Alan A. Ades 61,627,518 3,823,463 36,365,523 Robert Ades 61,626,993 3,823,988 36,365,523 Michael J. Driscoll 62,439,161 3,011,820 36,365,523 Prathyusha Duraibabu 63,265,527 2,185,454 36,365,523 David Erani 61,703,819 3,747,162 36,365,523 Jon Giacomin 47,474,289 17,976,692 36,365,523 Gary S. Gillheeney, Sr. 64,607,644 843,337 36,365,523 Michele Korfin 65,067,741 383,240 36,365,523 Arthur S. Leibowitz 45,170,021 20,280,960 36,365,523 Glenn H. Nussdorf 42,138,802 23,312,179 36,365,523 Gilberto Quintero 64,990,594 460,387 36,365,523”
Earnings Releases
Organogenesis Holdings Inc. reported first quarter ended March 31, 2023 results: revenue $107.6 million, net income Net loss of $3.0 million, EPS $(0.02) per share. Guidance raised.
“Surgical & Sports Medicine markets, today reported financial results for the first quarter ended March 31, 2023. First Quarter 2023 Financial Results Summary: • Net revenue of $107.6 million for the first quarter of 2023, an increase of $10.5 million compared to net revenue of $97.1 million for the first quarter of 2022. Net revenue for the first quarter of 2023”
Earnings Releases
Organogenesis Holdings Inc. reported the year ended December 31, 2022 results: revenue $450.9 million, net income $15.5 million. Guidance initiated.
“of 2022, compared to Adjusted EBITDA of $26.3 million for the fourth quarter of 2021, a decrease of $12.3 million. Fiscal Year 2022 Financial Results Summary: • Net revenue of $450.9 million for the year ended December 31, 2022, a decrease of 4% compared to net revenue of $467.4 million for the year ended December 31, 2021. Net revenue for the year ended December 31,”
Earnings Releases
Organogenesis Holdings Inc. reported the fourth quarter ended December 31, 2022 results: revenue $115.5 million, net income $7.5 million, EPS $0.06 per share. Guidance initiated.
“Medicine markets, today reported financial results for the fourth quarter and the year ended December 31, 2022. Fourth Quarter 2022 Financial Results Summary: • Net revenue of $115.5 million for the fourth quarter of 2022, a decrease of 10% compared to net revenue of $127.9 million for the fourth quarter of 2021. Net revenue for the fourth quarter of 2022 consists”
Earnings Releases
Organogenesis Holdings Inc. reported third quarter ended September 30, 2022 results: revenue $116.9 million, net income $0.2 million, EPS $0.00 per share. Guidance lowered.
“& Sports Medicine markets, today reported financial results for the third quarter ended September 30, 2022. Third Quarter 2022 Financial Results Summary: • Net revenue of $116.9 million for the third quarter of 2022, an increase of 3% compared to net revenue of $113.8 million for the third quarter of 2021. Net revenue for the third quarter of 2022 consists of: o”
Gilberto Quintero was appointed as independent director at Organogenesis Holdings Inc..
“the Company announced that each of Michele I. Korfin and Gilberto Quintero had been appointed by the board of directors to serve as an independent director”
Michele I. Korfin was appointed as independent director at Organogenesis Holdings Inc..
“the Company announced that each of Michele I. Korfin and Gilberto Quintero had been appointed by the board of directors to serve as an independent director”
Michael J. Driscoll was appointed as Independent Director at Organogenesis Holdings Inc..
“On February 17, 2022, the Company announced that Michael J. Driscoll, Ed.D. had been appointed by the board of directors to serve as an independent director of the Company effective as of February 15, 2022.”
Prathyusha Duraibabu was appointed as Independent Director at Organogenesis Holdings Inc..
“Prathyusha Duraibabu had been appointed by the board of directors to serve as an independent director of the Company effective as of November 19, 2021.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.